From AI Insider · Greg Bock · · 1m 30s
Remedy Robotics Secures $62M for AI Vascular Robot
Remedy Robotics gets $62 million to build AI robot for stroke treatment.
In brief
Remedy Robotics gets $62 million to build AI robot for stroke treatment. Remedy Robotics raised $62 million in Series B funding to advance its AI-enabled N1 robotic system toward clinical trials and potential FDA approval for neurovascular procedures including stroke treatment. Originally reported by AI Insider.
Funding Round Details
Remedy Robotics raised $62 million in Series B funding to advance its AI-enabled N1 robotic system toward clinical trials and potential FDA approval for neurovascular procedures including stroke treatment.
Investors and Use of Funds
The DCVC-led round included UC Investments, Skip Capital, Hostplus and existing investors, with proceeds supporting a planned University of California clinical trial, prototype deployments and further development of autonomous capabilities.
N1 System Capabilities
The N1 System is designed for on-site, remote and autonomous endovascular procedures but remains under development and is not approved for sale or clinical use in any jurisdiction.
CEO's Statement
Co-founder and CEO Dr. David Bell said the funding will help speed up development and deployment of the N1 System to make specialized care more widely accessible, regardless of location.
“Endovascular intervention is the gold standard treatment for stroke and many cardiovascular emergencies, yet access remains limited to a small number of hospitals.”
What's Next
Remedy plans to conduct a pivotal clinical trial in partnership with the University of California, deploy prototype N1 Systems through clinical partners and continue developing autonomous capabilities.
Technology and Impact
The N1 System uses machine learning to analyze medical images before procedures, simulate potential approaches and align three-dimensional and two-dimensional images in real time.
The key point
Remedy Robotics raised $62 million in Series B funding to advance its AI-enabled N1 robotic system toward clinical trials and potential FDA approval for neurovascular procedures including stroke treatment.
Read the TL;DR — this story on one card.





